文献速递免疫规划妇幼与学校卫生

婴儿通过接受尼塞韦单抗或母亲接种疫苗获得呼吸道合胞病毒免疫覆盖情况——美国,2023年10月至2024年3月

Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2025-08-21

美国33个州和哥伦比亚特区数据显示,2023年10月至2024年3月出生婴儿中估计29%获得RSV免疫,其中19%通过婴儿接受尼塞韦单抗、10%通过母亲接种RSV疫苗;各州覆盖率估计为11%至53%;接受尼塞韦单抗的婴儿中38%在出生后0-6天内接种。

要点

  • 2023年10月至2024年3月出生婴儿中估计29%获得RSV免疫,19%通过尼塞韦单抗、10%通过母亲接种疫苗。
  • 各州婴儿RSV免疫覆盖率估计范围为11%至53%。
  • 接受尼塞韦单抗的婴儿中38%在出生后0-6天内接受。

核心结论

  • 2023年10月至2024年3月出生婴儿中估计29%获得RSV免疫,需持续努力以提高婴儿和孕妇RSV免疫覆盖率。

研究设计与样本

  • 通过汇总33个州和哥伦比亚特区免疫信息系统中报告接受尼塞韦单抗的婴儿数和接受RSV疫苗的育龄妇女数,除以CDC WONDER natality数据的活产总数,估计婴儿RSV免疫覆盖率。

主要发现

  • 33个州和哥伦比亚特区中,2023年10月至2024年3月出生婴儿估计29%获得RSV免疫,其中19%通过婴儿接受尼塞韦单抗、10%通过母亲接种RSV疫苗。
  • 各州婴儿RSV免疫覆盖率估计范围为11%至53%。
  • 接受尼塞韦单抗的婴儿中38%在出生后0-6天内接受。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the United States. A new RSV monoclonal antibody (nirsevimab) for infants and an RSV vaccine for pregnant women were recommended by the Advisory Committee on Immunization Practices in August and September 2023, respectively, to protect infants against RSV infection. Sufficient data have become available to allow estimates of infant RSV immunization coverage through administration of these products. Among infants born during October 2023-March 2024, infant RSV immunization coverage was estimated by summing the total number of infants who received nirsevimab and the number of women of childbearing age who received RSV vaccine, as reported to immunization information systems (IISs) in 33 U.S. states and the District of Columbia (DC), and dividing by the total number of live births, obtained from CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) natality data. Across 33 states and DC, an estimated 29% of infants born during October 2023-March 2024 were immunized against RSV during the 2023-24 respiratory virus season, including 19% through infant receipt of nirsevimab and 10% through maternal RSV vaccination. Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11% to 53% by state. Among infants who received nirsevimab, 38% received it within the first week of life (0-6 days after birth). Continued efforts are needed to increase RSV immunization coverage among infants and pregnant women.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Boundy EO, Fast H, Jatlaoui TC, et al. Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024. MMWR Morb Mortal Wkly Rep. 2025. PMID: 40839535. doi:10.15585/mmwr.mm7431a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。